| 000 | 01383 a2200361 4500 | ||
|---|---|---|---|
| 005 | 20250515171439.0 | ||
| 264 | 0 | _c20090624 | |
| 008 | 200906s 0 0 eng d | ||
| 022 | _a1468-2060 | ||
| 024 | 7 |
_a10.1136/ard.2008.105940 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aScott, David L | |
| 245 | 0 | 0 |
_aNew tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice? _h[electronic resource] |
| 260 |
_bAnnals of the rheumatic diseases _cJun 2009 |
||
| 300 |
_a767-9 p. _bdigital |
||
| 500 | _aPublication Type: Editorial; Comment | ||
| 650 | 0 | 4 |
_aAnti-Inflammatory Agents _xeconomics |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xeconomics |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xdrug therapy |
| 650 | 0 | 4 | _aCertolizumab Pegol |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin Fab Fragments _xeconomics |
| 650 | 0 | 4 | _aPatient Selection |
| 650 | 0 | 4 |
_aPolyethylene Glycols _xeconomics |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 700 | 1 | _aCope, Andrew | |
| 773 | 0 |
_tAnnals of the rheumatic diseases _gvol. 68 _gno. 6 _gp. 767-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/ard.2008.105940 _zAvailable from publisher's website |
| 999 |
_c18863508 _d18863508 |
||